Design, Synthesis, and Validation of a β-Turn Mimetic Library Targeting Protein–Protein and Peptide–Receptor Interactions by Whitby, Landon R. et al.
Design, Synthesis, and Validation of a β-Turn Mimetic Library
Targeting Protein–Protein and Peptide–Receptor Interactions
Landon R. Whitby†, Yoshio Ando†, Vincent Setola‡, Peter K. Vogt†, Bryan L. Roth‡, and
Dale L. Boger†,*
† Department of Chemistry and The Skaggs Institute for Chemical Biology The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037
‡ NIMH Psychoactive Drug Screening Program, University of North Carolina Chapel Hill, Genetic
Medicine Building, Chapel Hill, North Carolina 27514
Abstract
The design and synthesis of a β-turn mimetic library as a key component of a small molecule
library targeting the major recognition motifs involved in protein–protein interactions is described.
Analysis of a geometric characterization of 10,245 β-turns in the protein data bank (PDB)
suggested that trans-pyrrolidine-3,4-dicarboxamide could serve as an effective and synthetically
accessible library template. This was confirmed by initially screening select compounds against a
series of peptide-activated GPCRs that recognize a β-turn structure in their endogenous ligands.
This validation study was highlighted by identification of both nonbasic and basic small molecules
with high affinities (Ki = 390 nM and 23 nM, respectively) for the κ-opioid receptor (KOR).
Consistent with the screening capabilities of collaborators and following the design validation, the
complete library was assembled as 210 mixtures of 20 compounds, providing a total of 4,200
compounds designed to mimic all possible permutations of 3 of the 4 residues in a naturally
occurring β-turn. Unique to the design and because of the C2 symmetry of the template, a typical
20 × 20 × 20-mix (8,000 compounds prepared as 400 mixtures of 20 compounds) needed to
represent 20 variations in the side chains of three amino acid residues reduces to a 210 × 20-mix,
thereby simplifying the library synthesis and subsequent screening. The library was prepared using
a solution-phase synthetic protocol with liquid–liquid or liquid–solid extractions for purification
and conducted on a scale that insures its long-term availability for screening campaigns. Screening
the library against the human opioid receptors (KOR, MOR, and DOR) identified not only the
activity of library members expected to mimic the opioid receptor peptide ligands, but also
additional side chain combinations that provided enhanced receptor binding selectivities (>100-
fold) and affinities (as low as Ki = 80 nM for KOR). A key insight to emerge from the studies is
that the phenol of Tyr in endogenous ligands bearing the H-Tyr-Pro-Trp/Phe-Phe-NH2 β-turn is
important for MOR binding, but may not be important for KOR (accommodated, but not
preferred) and that the resulting selectivity for KOR observed with its removal can be increased by
replacing the phenol OH with a chlorine substituent further enhancing KOR affinity.
boger@scripps.edu.
Supporting Information Available. Full experimental details on GPCR screening conditions and the library synthesis along with single
compound characterizations of all 20 monoamides (eq 1: 1H and 13C NMR, IR, and HRMS), a diagonal set of 20 Troc-diamides of
the full 210 matrix representing a member of each of the monamides and each of the R2 amine coupling reactions (eq 2: 1H and 13C
NMR, IR, and HRMS) confirming the compound structure and purity (>95%), a table summarizing the LCMS characterization of an
additional 50 Troc-diamides establishing their isolation (MS) and purity, compound characterizations of a second but different
diagonal set of 20 compounds in the full 210 matrix of diamide amines (eq 2: 1H and 13C NMR, IR, and HRMS), MS characterization
of a third diagonal set of 20 of the final 210 mixtures confirming the presence of all 20 components, the characterization of the 33
individual final triamides constituting deconvolution samples (1H NMR, MS), and three tables summarizing the isolated amounts and
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The interaction of proteins to form higher order complexes is critical to nearly all biological
processes, including cellular signaling.1 Despite their central role in cellular signaling, such
protein–protein interactions have emerged relatively slowly as viable small molecule
therapeutic targets.2 This can be attributed to the fact that protein–protein interfaces do not
typically bind endogenous small molecule ligands that could provide lead structures for drug
discovery programs and that the interfaces often also present physical challenges to small
molecule binding. These challenges are generally thought to come in the form of the
noncontiguous binding regions within the interacting proteins as well as an often relatively
large and/or flat binding interface. However, systematic case studies of selected protein–
protein interactions have revealed that there is typically a small cluster of key residues near
the center of the interface that contributes the majority of the recognition or binding
affinity.3 Significantly and although endogenous small molecule ligands may not exist,
many if not most protein–protein interactions are mediated by three main recognition motifs
(α-helix, β-turn, β-strand).4 Consequently, an attractive approach for the discovery of
modulators of protein–protein interactions is to mimic the key interaction residues using
small molecule mimetics of these three major recognition motifs.
A related class of interactions in which small molecule mimetics of peptide secondary
structure have already proven valuable is the peptide–receptor interactions, the best
characterized example of which is the interaction of the peptide-activated G protein-coupled
receptors (GPCRs) with their endogenous peptide ligands. Significantly, GPCRs comprise
the targets of over one-third of the currently registered pharmaceuticals, although only a
subset of GPCRs are peptide-activated. Although the peptide ligands of this subset of
GPCRs are usually flexible and able to adopt variable secondary structures, the active
conformation recognized by the receptor typically involves a turn structure (β- or γ-turn).5
Due to this pervasive recognition pattern, small molecule mimetics of turn structures
(typically β-turn)5 and peptides with turn constraints have been successful in targeting this
class of receptors.5,6 As the roles of these receptors have emerged, small molecule scaffolds
capable of mimicking peptide turn structures continue to be valuable in defining the residues
and secondary structure responsible for the binding recognition and affinity, useful in
validating new drug targets, and central to the subsequent development of new
therapeutics.6b
Over the past decade, we have enlisted a simple solution-phase library synthesis protocol,
complementary to more conventional solid-phase techniques, for the generation of libraries
capable of targeting protein–protein or protein–DNA interactions.7 The protocol employs
acid/base liquid–liquid or liquid–solid extractions for the purification of products (>95%
pure irrespective of the reaction efficiency), and offers the advantages of a less limiting
scale, expanded repertoire of chemical reactions (use of heterogeneous catalysts and
reagents), direct production of soluble intermediates and final products for assay, and the
lack of required linking, attachment and detachment, or capping steps. The approach is
amenable to convergent synthetic strategies, the synthesis of mixture libraries, or the use of
dynamic libraries. Notably, a number of effective small molecule modulators of protein–
protein7–12 or protein–DNA interactions13 have been identified from screening the libraries
prepared to date.
Recently, we initiated a program to expand our current library of 95,000 compounds2f,7 with
the preparation of a comprehensive small molecule library designed to mimic the three
major recognition motifs that mediate protein–protein interactions, namely the α-helix, the
β-turn, and the β-strand. Three libraries built around templates designed to mimic each
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secondary structure and substituted with all triplet combinations of groups representing the
20 natural amino acid side chains would contain a member capable of mimicking the key
interaction residues of many, if not most, protein–protein interactions.4 Such a library would
provide a powerful tool to interrogate protein–protein interaction networks in order to
validate new therapeutic targets, to provide therapeutic lead compounds, and to afford
modulators of biological processes for study. The screening of the comprehensive library
would not only provide lead structures for many protein–protein interaction targets even if
the nature of the interaction is unknown, but it can also be expected to yield key insights into
the recognition motif and key residues mediating the interaction.14 Screening of the library
would also provide an initial comprehensive structure–activity relationship (SAR) study for
subsequent iterative lead optimization.14 Notably, the β-turn component of this library
would be particularly valuable for the protein- and peptide-activated GPCRs that recognize
turn structures in their endogenous ligands.4,5 To date we have disclosed the design,
synthesis and validation of an 8,000-membered α-helix mimetic component of this library15
and we disclose herein the second component of this comprehensive library, a β-turn
mimetic library targeting protein–protein and peptide–receptor interactions.
Results and Discussion
β-turn mimetic design
The β-turn is one of the three main secondary structural motifs found in proteins and
peptides and occurs where the polypeptide strand reverses direction. As illustrated in Figure
1, the β-turn consists of four amino acid residues designated i to i+4 in which the distance
between Cαi and Cαi+3 is 7 Å. Several different types of β-turns exist, depending on the
dihedral angles ψ and ϕ of the i+1 and i+2 residues.
Small molecule mimetics of β-turns have been extensively investigated and utilized to
discover compounds that can mimic or disrupt β-turn mediated recognition events.16,17 An
ideal β-turn mimetic scaffold around which to build a screening library would be constrained
to approximate the correct geometric display of the amino acid side chain functionality
found within a β-turn, be sufficiently flexible to allow the side chains to approximate the
side chain vectors of the many turn types, and be amenable to robust library synthesis.
We envisioned a β-turn mimetic scaffold that could be substituted with all triplet
combinations of groups representing the 20 natural amino acid side chains that was
amenable to substitution using our solution-phase library synthesis protocol. This would
enable production of a library of pure compounds (>95%) on a scale that would permit
virtually unlimited screening opportunities and enable efficient optimization of lead
compounds through the rapid synthesis of subsequent lead optimization libraries. In order to
identify a template that would allow the appropriate geometric display of the amino acid
side chain functionality, we utilized a geometric analysis of the mean distances found
between α-carbon centers in a set of 10,245 β-turns in the protein data bank (PDB, Figure
2).18,19
Recognizing that one of the turn amino acids (i+1 or i+2) often serves a structural rather
than a recognition role (e.g., Pro or Gly),4,18 we sought to mimic Cα triplets in which either
Cαi+1 or Cαi+2 is omitted (i.e., Cαi, Cαi+2, Cαi+3 or Cαi, Cαi+1, Cαi+3). From this analysis,
we found that trans-pyrrolidine-3,4-dicarboxamide could serve as a synthetically accessible
template upon which to display the amino acid side chain groups (Figure 3A). Rigidified by
an intramolecular H-bond, the lowest energy conformation of the trans-pyrrolidine-3,4-
dicarboxamide has substituted centers that conform closely to the triangle geometries of the
Cα triplets found in Figure 2 in which either Cαi+1 or Cαi+2 is omitted (Figure 3B). An
overlay of the low energy conformation with the peptide backbone of a type I β-turn (Figure
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4A and 4B) demonstrates a potential mode of mimicry and yielded an rmsd value of 0.26 Å
for ethyl substituted centers versus the Cα triplet Cαi, Cαi+2, Cαi+3. In line with the design,
the non-covalent constraints that stabilize the lowest energy conformer also permit a degree
of flexibility to allow the compound to adopt variable H-bond donor/acceptor patterns
(which carbonyl is exo or endo in pseudo 7-member ring) and permit the attached side
chains to approximate the correct vector display of amino acid side chains in a wide range of
β-turn structures.18 Significantly, the trans-pyrrolidine-3,4-dicarboxamide can be
substituted using amide coupling reactions and possesses a simplifying C2 symmetry axis
that allows all triplet combinations of 20 different side chains to be accomplished with only
4,200 compounds (versus 8,000). Thus, in addition to potentially serving as a -turn mimetic
accurately matching the triangle geometries of the Cα triplets of a -turn while flexibly
accommodating the vector displays of side chains in a wide range of β-turn structures,18 it
also possesses a unique simplifying C2 symmetry and is functionalized in a manner
amenable to library synthesis.
Evaluation and validation of the design against peptide-activated GPCRs: the opioid
receptors
In order to establish the ability of substituted trans-pyrrolidine-3,4-dicarboxamides to
modulate βturn mediated recognition events and before embarking on a comprehensive
library synthesis, the evaluation of a select series of compounds against a representative set
of peptide-activated GPCRs that are thought to recognize β-turns in their endogenous
ligands was conducted. The μ-opioid receptor (MOR) is a well known clinical target for the
treatment of pain. MOR selective opiate analgesics such as morphine remain the drugs of
choice for the treatment of severe pain, but their use is limited by the well-characterized side
effects of respiratory depression, desensitization with chronic use (tolerance), and
development of dependence. The additional two members of the opioid receptor family, the
κ-opioid and δ-opioid receptors (KOR and DOR), have also been investigated as analgesic
targets. DOR agonists produce analgesia, but may also exhibit side effects including
convulsions. Activation of the KOR in the central nervous system produces analgesia,
though it is generally accompanied by dysphoria, hallucinations, and sedation. Targeting of
peripheral KOR, however, has emerged as a potentially promising treatment for
inflammatory and visceral pain as well as arthritis.20
Two highly potent and selective endogenous peptide ligands of the MOR are endomorphin-1
(H-Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (H-Tyr-Pro-Phe-Phe-NH2).21 Additional
endogenous agonists include Met-enkephalin (H-Tyr-Gly-Gly-Phe-Met-OH) and Leu-
enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH) that show high affinity for MOR and DOR, their
longer peptide precursors β-endorphin and dynorphin, as well as their C-terminus truncated
neoendorphin peptides that display high affinity for the KOR.20 Although some uncertainty
remains, there is considerable evidence that the active conformation of the endomorphins is
a β-turn, including activities observed by analogues that incorporate turn constraints and
appropriately substituted β-turn mimetics.22 Therefore, we prepared a small series of
pyrrolidine-3,4-dicarboxamide derived compounds designed to mimic the three side chain
residues in the pharmacophores of the endomorphins and enkephalins along with several Ala
negative controls (17–22) and measured their binding (Ki values) to MOR, KOR and DOR
(Figure 5). The highest affinity for the MOR was exhibited by compound 10 with the R1/R2
combination of Trp/HoPhe and R3 of Tyr (Ki = 820 nM) followed by compound 8 with R1/
R2 of Trp/Phe and R3 of HoTyr (Ki = 930 nM). In addition to exhibiting submicromolar
activity using a simple template, the activity reflected a combination of side chain residues
found in the endogenous endorphin ligands. Moreover, comparisons among the compounds
examined demonstrated that the best affinity to MOR was observed when single carbon
extensions of key side chains (HoPhe or HoTyr) were incorporated into the structure and
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this influenced our selection of side chains incorporated into the full library design.
Interestingly, the compounds showed much higher affinities for the KOR than for the MOR,
highlighted by 8 and 9 with Ki values measured at 390 nM and 23 nM, respectively (Figure
6). The identification of 9 as the most active compound is easy to appreciate considering that
the R3 Tyr side chain is attached to the pyrrolidine nitrogen via an alkyl rather than acyl
linkage giving rise to the familiar tyramine group bearing a free amine found in the
“message” structure of nearly all opioid analgesics and peptides (Figure 6B).20a However,
even its N-acyl variant lacking the basic nitrogen (8, Ki = 390 nM) proved remarkably
effective. Selectivity for KOR binding was observed with 9 (~100 fold) and this trend was
observed with nearly all compounds tested. The origin of this selectivity is currently
undefined, but its consistency across the range of compounds tested suggests that there are
intrinsic properties to the trans-pyrrolidine-3,4-dicarboxamide template, including its 3-
dimensional projection of side chains or interactions made by the template itself, that favor
KOR binding. Nevertheless, the high nanomolar affinities of compounds 8 and 10 indicate
that the trans-pyrrolidine-3,4-dicarboxamide template can effectively mimic the active turn
structure of the endomorphins.
Synthesis of the β-turn mimetic library
Convinced that the pyrrolidine-3,4-dicarboxamide template would prove to be a valuable β-
turn mimetic and having established subtle design features from the exploratory studies, the
synthesis of the comprehensive β-turn mimetic library was initiated. The 20 amino acid side
chain groups utilized to construct the library along with corresponding protecting groups are
provided in Figure 7. By substituting each position of the trans-pyrrolidine-3,4-
dicarboxamide template with all combinations of these 20 groups, a total of 4,200
compounds are produced representing all possible permutations of 3 of the 4 residues in a
naturally occurring β-turn. Due to the perceived degeneracy of incorporating the side chains
of both aspartic and glutamic acid as well as asparigine and glutamine, only the side chains
of glutamic acid (Glu) and glutamine (Gln) were used in the library. Similarly, an arginine
side chain was omitted, but the side chain of lysine (Lys) was incorporated. No attempt to
incorporate a cysteine side chain was made due to anticipated stability and storage problems.
Finally, the side chains of glycine and proline were omitted due to their expected minor role
in recognition events. These six natural amino acid side chain omissions were replaced with
additional unnatural aromatic side chain groups that often dominate protein–protein and
protein–peptide interactions or with groups that represent one carbon extensions of such
residues. Thus, O-methyl tyrosine (TyrMe), naphthyl (Nap), and 4-chlorophenylalanine
[Phe(4Cl)] were included in the library as well as the side chains of the one carbon extension
residues homophenylalanine (HoPhe), homotyrosine (HoTyr) and 4-
chlorohomophenylalanine [HoPhe(4Cl)]. Having selected the 20 groups to incorporate into
the library, they were used in their terminal amine form (for incorporation into the R1/R2
positions) or terminal carboxylic acid form (for incorporation into the R3 position) for the
library synthesis.
The retrosynthetic analysis for the construction of the library is shown in Scheme 1. We
anticipated that the final 4,200 compound library would be obtained by acylation of 210
individual trans-pyrrolidine-3,4-dicarboxamides at the pyrrolidine nitrogen using an
equimolar mixture of the carboxylic acids of the 20 selected side chains (210 × 20-mix). The
order of the side chain introductions (amide couplings; R1, R2, and R3) and the location of
the 20-mix functionalization (R3) were dictated by the C2 symmetry of the template and the
simplifying opportunity it presented for the number of compounds required to represent all
20 × 20 × 20-mix combinations (210 individual R1/R2 combinations x 20-mix for R3). The
210 individual amines were anticipated to be derived from their 2,2,2-
trichloroethoxycarbonyl (Troc) protected precursors, which were individually synthesized
Whitby et al. Page 5













starting from the mono methyl ester of trans-N-Troc-pyrrolidine-3,4-dicarboxylic acid
utilizing a straightforward amide coupling, methyl ester hydrolysis, and amide coupling
reaction sequence. In turn, the mono methyl ester was to be prepared from the N-
benzylpyrrolidine mixed benzyl methyl ester using hydrogenolysis of the benzyl group
followed by Troc protection of the free amine. Finally, the trans-N-benzylpyrrolidine-3,4-
dicarboxylic acid benzyl methyl ester could be accessed using a [3+2] dipolar cycloaddition
between the mixed fumarate ester and the azomethine ylide precursor N-benzyl-N-
methoxymethyl-N-(trimethylsilyl)methylamine.23
The synthesis of the mono methyl ester of trans-N-Troc-pyrrolidine-3,4-dicarboxylic acid
(26) is shown in Scheme 2. The azomethine ylide precursor N-benzyl-N-methoxymethyl-N-
(trimethylsilyl)methylamine (23) was prepared as described23 by condensing benzylamine
with chloromethyltrimethylsilane to yield N-benzyl-N-(trimethylsilyl)methylamine,
followed by treatment with formaldehyde/H2O/MeOH in the presence of K2CO3. This
material was employed in a [3+2] dipolar cycloaddition with the mixed fumarate ester in the
presence of LiF and under ultrasound conditions to give 24 in multigram quantities.23 This
material was further elaborated to the amino acid 25 by hydrogenolysis removal of the
benzyl groups [H2, Pd(OH)2] followed by Troc protection of the pyrrolidine nitrogen using
2,2,2-trichloroethyl chloroformate to provide 26.
With the starting template in hand, the library diversification began with the first amide
coupling using 20 primary amines under EDCI/HOAt mediated coupling conditions to
provide the monoamides (eq 1 and Figure 8), which were fully characterized by 1H and 13C
NMR, IR, and HRMS (Supporting Information). Methyl ester saponification (LiOH)
provided the individual 20 monosubstituted carboxylic acids in high yields.
(1)
The next stage in the library synthesis entailed preparation of the 210 trans-pyrrolidine-3,4-
dicarboxamides (eq 2). The Troc-protected dicarboxamides were prepared by amide
coupling (EDCI, HOAt, 2,6-lutidine, DMF, 25 °C, 14 h) and this enabled isolation and
purification of the products (62–100% yield) using acid/base liquid–liquid extractions in
which all reagents, reagent byproducts, and any unreacted starting materials were removed.
A diagonal set of 20 diamides of the full 210 matrix, representing a member of each of the
monamides and each of the R2 amine coupling reactions, was fully characterized (1H
and 13C NMR, IR, and HRMS) confirming both the compound structure and purity (>95%)
(Supporting Information). The subsequent Troc deprotection was conducted using activated
zinc nanopowder (20 equiv) in 2:1 THF/AcOH (25 °C, 8 h).24 Following zinc treatment, the
compounds were isolated by filtration through Celite to remove the zinc and removal of the
solvent in vacuo with a toluene azeotrope. Residual AcOH was completely removed by
dissolving the compound in MeOH and passing it through a small column of basic silica gel
(Chromatorex NH, Fuji Silysia Ltd). This procedure provided highly pure amines (> 95%) in
good yields (product yields and amounts in Supporting Information) and avoided the use of
an aqueous base extraction, which was found to result in low product recovery in certain
cases due to the aqueous solubility. As before, a representative but different diagonal set of
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20 compounds of the full 210 matrix was fully characterized by 1H and 13C NMR, IR, and
HRMS (Supporting Information).
(2)
The final library was obtained by coupling (EDCI, HOAt, 2,6-lutidine, DMF, 25 °C, 12 h)
each of the 210 amines with an equimolar mixture of the carboxylic acids of the 20 groups
shown in Figure 10 (eq 3). To ensure that each of the 20 carboxylic acids was fully
consumed to yield an equimolar mixture of 20 products, 1.2 equivalents of the free amine
was employed in each coupling reaction. The excess starting amine was subsequently
removed upon completion of the reaction using aqueous acid extractions. The final global
deprotection of all side chain protecting groups was accomplished by treatment with 3:1:1
TFA/MeOH/H2O (25 °C). Using this condition, complete removal of Boc, tert-butyl ester,
TIPS, and trityl groups was observed in 12–16 h. We then verified that all final products in
20 representative final mixtures were detected by MS using a third diagonal 20/210 matrix
characterization (see Supporting Information).
(3)
To confirm the quality of the construction of the library as 20 compound mixtures, a
representative final library mixture was selected for comparison by HPLC to an authentic
equimolar mixture prepared from the individually synthesized compounds (Figure 9).
Although a separation of all 20 mixture components is not possible on a single HPLC run,
the nearly identical detection profiles displayed by the two mixtures confirms that not only
are all 20 compounds present in the library mixture, but that they must be present in amounts
that approach equimolar.
Screening the library against the opioid receptors
The entire library composed of 210 mixtures of 20 compounds (210 wells) was screened at
10 μM (total concentration, 0.5 μM per compound) for activity at opioid receptors in
radioligand binding assays at human cloned receptors (KOR, MOR, and DOR). The
summary of the screening results for the KOR and MOR is shown in Figure 10. The overall
trends against the three receptors proved consistent with our previous single compound
results in exhibiting an intrinsic binding selectivity of the trans-pyrrolidine-3,4-
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dicarboxamides for the KOR, followed by the MOR and then DOR (data not shown). A
clear SAR trend is evident from the primary screening results even without the examination
of individual compounds, illustrating that hydrophobic aromatic side chains generally
dominate the interaction with the opioid receptors, with Phe(4Cl), Trp, and Nap showing
strong inhibition against the KOR and the HoTyr, Trp, and HoPhe(4Cl) side chains ranking
among the best against the MOR. The exception to this trend with both the KOR and MOR
was the potent inhibition observed with a basic His side chain in the R1/R2 position, with a
particularly potent R1/R2 combination being His and a bulky aliphatic residue (Val or Leu).
Deconvolution of selected mixtures and screening of individual compounds
Based on the primary screening data for the library and with the recognition β-turn sequence
of the endomorphins (H-Tyr-Pro-Trp/Phe-Phe-NH2) in mind, three related mixtures were
selected for deconvolution (Figure 11). The series containing R1/R2 side chains Trp and Phe
is the closest representative within the library of the endomorphin-1 sequence and contains
compound 8, which exhibited the measured Ki values of 390 nM and 930 nM for KOR and
MOR, respectively. The Trp/Phe(4Cl) series represents a closely related series to the Trp/
Phe series, but the addition of the 4-Cl substituent enhanced binding of the mixture to both
the KOR (86% vs 73% inhibition) and the MOR (66% vs 56% inhibition). Its deconvolution
could be expected to yield individual compounds with enhanced affinity to both receptors
while also allowing a further evaluation of the β-turn mimicry of the compounds. The final
series chosen for deconvolution, the Phe(4Cl)/Phe(4Cl) series, was the mixture that
displayed the highest affinity against the KOR (91% inhibition) and also the greatest
difference between KOR and MOR affinity (91% vs 48%). These three mixtures were
deconvoluted by resynthesis of the individual compounds from the three archived
penultimate intermediates using the conditions found in equation 3 to yield 60 individual
compounds for screening.
The 60 individual compounds were screened at 10 μM for activity at the KOR and MOR via
the radioligand binding assays. Because of the lower activity at the MOR, where the %
inhibition was not pegged at levels approaching 90% for each series, the general trends were
clearest in examining its results. The R3 side chain preferences for the individual compounds
against the MOR are shown below (Figure 12). According to the proposed mode of β-turn
mimicry by the compounds and the sequence of the MOR selective endomorphins, Tyr or
HoTyr would be expected to be the favored side chain at the R3 position if mimicry of an
endomorphin β-turn is being achieved. Consistent with this expectation, the screening
demonstrated that either HoTyr or Tyr was the favored R3 substituent in all three series, with
HoTyr performing best in the Trp/Phe and Trp/Phe(4Cl) series and Tyr yielding the most
potent compound in the Phe(4Cl)/Phe(4Cl) series. Beautifully, and if the turn recognition
motif were unknown, these results would represent the identification of the Tyr-XXX-Trp-
Phe and Tyr-XXX-Phe-Phe β-turn motifs. This result also reinforced our earlier decision to
incorporate singe carbon extensions of key side chains such as Tyr into the library. In
general, other aromatic R3 side chains were less active but roughly equal in potency and all
were typically more active than compounds bearing the aliphatic or charged side chains
regardless of the series.
The data from each of the three deconvolution series is shown in Figure 13. Clear from these
comparisons is the greatest activity against the KOR (KOR > MOR > DOR) for all three
series and that the activity of the three series generally follows the order of Phe(4Cl)/
Phe(4Cl) > Trp/Phe(4Cl) > Trp/Phe as observed in the original mixture screening results
(Figure 11). The excellent activity of 8 (Ki = 390 nM) used originally to test the design and
found in the Trp/Phe series was improved with the replacement of Phe with Phe(4Cl) in the
Trp/Phe(4Cl) series providing 28 (Ki = 250 nM, Figure 14A) and this series provided several
related compounds that exhibited Ki’s of < 300 nM. Finally, the most active Phe(4Cl)/
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Phe(4Cl) series not only showed a greater activity for the KOR, but it also exhibited a
greater selectivity for the KOR versus the MOR or DOR as inferred from the original
mixture screening results (Figure 11). The most potent compound in this series for the KOR
was 29 (Ki = 80 nM, Figure 17B) that was found to be >100-fold selective versus the MOR
or DOR (Ki >10,000 nM).
As detailed earlier, the trends for MOR binding illustrated that the HoTyr [Trp/Phe, Trp/
Phe(4Cl)] or Tyr [Phe(4Cl)/Phe(4Cl)] were the clearly favored R3 substituent in all three
series indicative of a prominent or productive role for the Tyr free phenol. Other aromatic
R3 side chains were less active and roughly equal in potency (Figure 12). This unique
preference for HoTyr or Tyr and the presence of the free phenol was not observed with
KOR. While still preferring a third aryl R3 side chain substituent [Phe(4Cl), HoTyr > Tyr =
Tyr(Me), Phe > HoPhe(4Cl), > Trp, HoPhe > Nap] and accommodating the free phenol of
Tyr, it no longer exhibits a phenol preference, Figure 15. Without over interpreting the
minor differences in the measured and sometimes pegged assay values, there was virtually
no difference in Tyr and Tyr(Me) for each of the three series indicating that protection of the
phenol as a methyl ether has no impact in binding affinity, and both were nearly identical to
Phe itself in each of the three series. Among the best of the R3 substituents in nearly each of
the three series was Phe(4Cl) and HoPhe(4Cl). In addition to suggesting that the Tyr free
phenol of the endomorphins and enkephalins may not be important to KOR binding,25 it
also suggests that a way to enhance KOR versus MOR and DOR binding selectivity is to
remove this pharmacophore phenol OH. Like the behavior of 29, further enhancements in
KOR affinity may be achieved by utilizing Phe(4Cl) resulting in higher affinity and even
more selective KOR ligands.
Conclusions
The solution-phase synthesis of a β-turn mimetic library as the second component of a
general small molecule library targeting the key recognition motifs involved in protein–
protein interactions is described. Using a geometric characterization of β-turns in the PDB,
the trans-pyrrolidine-3,4-dicarboxamide was proposed and subsequently found to serve as
an effective and synthetically accessible library β-turn mimetic template and this was
initially validated by screening test compounds against a series of peptide-activated GPCRs
that recognize β-turn structure in their ligands. The screening of selected compounds
designed to mimic the β-turn pharmacophore of the peptide ligands of the opioid receptors
demonstrated that appropriately substituted trans-pyrrolidine-3,4-dicarboxamides could
replace the peptide backbone for effective display of side chain groups in a β-turn. This
validation was highlighted by identification of both nonbasic and basic small molecules with
high affinity (Ki = 390 nM and 23 nM, respectively) for the κ-opioid receptor (KOR). The
library was assembled using a solution-phase protocol to provide 210 mixtures of 20
compounds for a total of 4,200 compounds designed to mimic all possible permutations of 3
of the 4 residues in a naturally occurring β-turn. Even if the recognition motif is unknown or
unrecognized, the library screening should provide lead structures, provide insights into the
nature of the interaction (β-turn), and identify the key amino acid residues responsible for
the protein–protein or peptide–receptor interaction. Additionally, the use of such a
comprehensive library can take advantage of the principles of selection to discover
compounds with improved properties (e.g., of affinity, selectivity) over those that mimic the
endogenous protein or peptide ligands. The screening of the complete library against the
opioid receptors demonstrated that not only could the expected activity be observed with
library mixtures containing the compounds shown to mimic the opioid receptor endogenous
peptide ligands, but that additional side chain combinations could be identified with even
higher receptor binding affinities and selectivity providing new insights into the -turn
recognition events.
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Schematic diagram of a β-turn.
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Mean and standard deviations of the Cα distances taken from a set of 10,245 β-turns in the
PDB.
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(A) The trans-pyrrolidine-3,4-dicarboxamide template. (B) Low energy conformation and
measured distances between substituted centers of a trans-pyrrolidine-3,4- dicarboxamide
with ethyl substituents. (C) A trans-pyrrolidine-3,4-dicarboxamide substituted with groups
representing the side chains of Leu, Phe, and His.
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(A) Overlay of a potential mode of β-turn mimicry by a trisubstituted trans-pyrrolidine-3,4-
dicarboxamide. (B) Overlay and calculated rmsd value for attachment of the three
substituted centers of the template with three α-carbons in a type I β-turn.
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Screening data of compounds against μ-opioid receptor (MOR) and κ-opioid receptor
(KOR).
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(A, B) Structures of high affinity, KOR selective compounds 8 and 9. The tyramine
pharmacophore found in the “message” structure of opioid compounds and peptides is
highlighted in B.
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The 20 groups used in the synthesis of the β-turn mimetic library.
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Synthesized 20 monoamides with coupling yields and product amounts.
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HPLC comparison of library (EXP 1) and authentic (EXP 2) equimolar mixture of final 20
compounds derived from 27. HPLC conditions: linear gradient 0–90% MeCN in H2O over 7
min, then 90% MeCN for 10 min at flow rate of 0.75 mL/min.
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(A) % inhibition of [3H]U69593 binding for the indicated R1/R2 side chain combinations in
the screening of the 210 mixtures against the KOR. (B) % inhibition of [3H]DAMGO
binding for the indicated R1/R2 side chain combinations in the screening of the 210 mixtures
against the MOR.
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Mixtures selected for deconvolution.
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Screening results (% inhibition at 10 μM) for the three series of deconvolution compounds
against MOR along with measured Ki values (nm) (vs [3H]DAMGO).
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Screening results (% inhibition at 10 μM) for the three series of deconvolution compounds
against KOR (vs [3H]U69593), MOR (vs [3H]DAMGO), and DOR (vs [3H]DADLE) along
with measured Ki values (nM) against KOR.
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Chemical structures of compounds with highest affinity for KOR from the Trp/Phe(4Cl)
series (28) and the Phe(4Cl)/Phe(4Cl) series (29).
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Screening results (% inhibition at 10 μM) for the three series of deconvolution compounds
against KOR (vs [3H]U69593).
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Retrosynthetic plan for construction of the β-turn mimetic library.
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